Oncorus IncNASDAQ ONCR Stock Report

Oncorus, Inc. engages in the research and development of a viral immunotherapy platform. The company is headquartered in Andover, Massachusetts and currently employs 82 full-time employees. The company went IPO on 2020-10-02. The firm is focused on developing active viral immunotherapies to transform outcomes for cancer patients. Using its two platforms, the Company is developing a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and deliver transgenes to stimulate multiple arms of the immune system against tumors. Its lead product candidate, ONCR-177, is an intratumorally administered viral immunotherapy based on its oncolytic HSV-1 platform (oHSV Platform), which leverages the Herpes Simplex Virus type 1 (HSV-1). The company is also developing a pipeline of product candidates based on its vRNA Immunotherapy Platform. This platform aims to enable repeat intravenous administration of viral immunotherapies in order to treat cancers that are less amenable to intratumoral injection due to safety and feasibility reasons, such as cancers of the lung.